Livelsberger Financial Advisory Biogen Inc. Transaction History
Livelsberger Financial Advisory
- $4.77 Billion
- Q3 2024
A detailed history of Livelsberger Financial Advisory transactions in Biogen Inc. stock. As of the latest transaction made, Livelsberger Financial Advisory holds 100 shares of BIIB stock, worth $14,990. This represents 0.41% of its overall portfolio holdings.
Number of Shares
100Holding current value
$14,990% of portfolio
0.41%Shares
2 transactions
Others Institutions Holding BIIB
# of Institutions
1,037Shares Held
126MCall Options Held
1.13MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.5 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.45 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.18 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.1 Billion0.06% of portfolio
-
Jpmorgan Chase & CO New York, NY5.26MShares$788 Million0.08% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $21.6B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...